Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 110.53 0.79 (0.72%) Market Cap: 6.97 Bil Enterprise Value: 10.88 Bil PE Ratio: 22.79 PB Ratio: 1.88 GF Score: 78/100

Q3 2021 Jazz Pharmaceuticals PLC Earnings Call Transcript

Nov 09, 2021 / 09:30PM GMT
Release Date Price: $132 (-0.98%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2021 Jazz Pharmaceuticals Earnings Conference Call. (Operator Instructions)

I would now like to turn the conference over to your host, Ms. Andrea Flynn, Head of Investor Relations. Ma'am, please go ahead.

Andrea N. Flynn
Jazz Pharmaceuticals plc - VP & Head of IR

Thank you, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its third quarter 2021 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website.

On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, Executive Vice President and Chief Financial Officer; Dan Swisher, President; and Rob Iannone, Executive Vice President, R&D and Chief Medical Officer. Kim Sablich, Executive Vice President and General Manager of North America; and Phil Jochelson, Neuroscience Therapeutic Head, will join for Q

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot